Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective diligently but unsuccessfully to create an one-time therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my last few shares. My first CytoDyn post, “CytoDyn: What To Do When It is Too Good To Be True?”, set away all of the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan offered such a highly promotional image in the Uptick Newswire employment interview that I came away with a poor opinion of the company.

Irony of irony, the poor viewpoint of mine of the business enterprise has grown steadily, though the disappointment has not been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of the technology and associated intellectual property coming from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 million) and the first new drug application approval ($five million), and also royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and numerous therapies, it’s this individual therapy and a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy of dozens of indications.

Its opening banner on its site (below) shows an active company with diverse interests albeit focused on leronlimab, multiple illness sorts, multiple publications in addition to multiple delivering presentations.

Could it all be smoke cigarettes and mirrors? That is a question I have been asking myself through the very start of my interest in this particular business. Judging with the multiples of thousands of several remarks on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this particular question.

CytoDyn is a traditional battleground, or even some might say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *